Outcomes and Safety of History-Based Screening for Medication Abortion

Authors:

Abstract
Each year nearly 1 million people in the US seek an induced abortion.1 Medication abortion with mifepristone and misoprostol is currently approved by the US Food and Drug Administration (FDA) for use through 70 days of pregnancy,2 although based on evidence, many clinicians offer it up to 77 days.3,4 Typically, clinicians perform ultrasonography or a pelvic examination before treatment to determine the duration and location of the pregnancy. However, during the COVID-19 pandemic, some clinics relied on patient history alone, without ultrasonography or pelvic examination, to reduce physical contact.5-8 In 2020, the FDA temporarily relaxed its in-person dispensing requirement on mifepristone for the duration of the pandemic.9 By October 2020, guidelines issued by the Society of Family Planning,10 the American College of Obstetricians and Gynecologists10 and the National Abortion Federation11 had been amended to endorse this no-test approach, providing abortion medications without ultrasonography or other facility-based tests.12 Together, these changes enabled the emergence of several new online services that offered medication abortion entirely remotely using telemedicine and mail.13,14

This publication has 35 references indexed in Scilit: